Rebastinib(DCC-2036;DCC2036) is an inhibitor of tyrosine kinases TIE2 and ABL1.Rebastinib(DCC2036) can prevent primary tumor growth and lung metastasis in the PyMT breast cancer model. Rebastinib is approximately 50 times more potent as an inhibitor of TIE2 than BCR-ABL.